We believe that our equine family members deserve the same high quality therapies that human family members enjoy.
We identify therapies (pharmaceuticals, biologics, medical devices) and targeted diseases that have been validated in humans and develop animal versions to treat and cure pets. We seek to leverage the investments that have been made in human pharmaceutical R&D to develop therapies for horses with lower risk, lower cost, and shorter time-to-market, compared to human drug development.
We believe KindredBio can deliver superior returns to investors because while the market sizes for pet drugs are about 10-fold smaller compared to human market sizes, the cost of development is 100-fold less.
World Class Team
KindredBio is one of the first veterinary biotech companies in the world, and we have a world-class team, including a former Director of FDA’s Center for Veterinary Medicine and a former Head of Biotherapeutics Clinical Research at Genentech. Because of our broad based and experienced team, and because we do not outsource our clinical studies, we can move at a very rapid pace. We anticipate 2 product launches in less than 2 years.
In addition, in the technically demanding area of biologics, KindredBio has one of the most experienced teams in the pharmaceutical industry, with experts drawn from companies like Genentech and Amgen. We also have access to some of the most cutting-edge antibody technologies.
To contact investor relations, or to request an investor packet, please call 650.701.7904 or email IR@kindredbio.com.